Update on Escherichia coli O157:H7

Current Gastroenterology Reports
J Mark Lawson

Abstract

Escherichia coli O157:H7 infection is one of the more intriguing emerging infectious diseases of the industrialized world. The clinical importance of this organism first came to light in the 1980s and has been associated with significant morbidity and mortality in the United States. The infection is more common in industrialized countries than developing ones and is most closely associated with asymptomatic colonization of cattle. Fecal oral transmission is the rule, with the inoculum needed for infection much smaller than that required for E. coli-related travelers' diarrhea. The organism can survive for months in the environment, and cross contamination is common. Watery diarrhea that progresses to bloody diarrhea without prominent fever is the classic presentation. The classic biopsy finding is similar to that of ischemic colitis, with acute inflammation and hemorrhage involving the superficial mucosa with preservation of the deeper crypts. E. coli O157:H7 has powerful Shigella-like toxins that are encoded by bacteriophages and can trigger thrombotic complications such as the hemolytic uremic syndrome or thrombotic thrombocytopenic purpura. The very young and the elderly are most at risk for serious disease and complications...Continue Reading

References

Apr 16, 1998·The Journal of Infectious Diseases·L SlutskerP M Griffin
Jan 29, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K GrifF Allerberger
Oct 12, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T KuriokaE Kita
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S DundasS J Hutchinson
Aug 23, 2002·JAMA : the Journal of the American Medical Association·Nasia SafdarDennis G Maki
Aug 23, 2002·The New England Journal of Medicine·John A CrumpThomas J Van Gilder
Aug 23, 2002·The New England Journal of Medicine·Joel L Moake
Aug 23, 2002·The New England Journal of Medicine·Sarah J O'Brien, Goutam K Adak
Jan 28, 2004·The Journal of Infectious Diseases·Miho WatanabeKiyotaka Nishikawa
Mar 30, 2004·The American Journal of Gastroenterology·David B HuangHerbert L DuPont

❮ Previous
Next ❯

Citations

Feb 1, 2007·Clinics in Colon and Rectal Surgery·Harry T Papaconstantinou, J Scott Thomas
Feb 24, 2006·Emerging Infectious Diseases·Mio SakumaNobuhiko Okabe
May 22, 2009·Gastroenterology·Lori R HoltzPhillip I Tarr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.